Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy.

CLIA certification is a U.S. regulatory requirement for laboratories performing testing on specimens from humans, such as blood, body fluids, and tissue. The agreement represents the first commercial validation of Allarity’s CLIA-certified laboratory services strategy following the Company’s receipt of CLIA certification in July 2026.

Under the agreement, Allarity will provide a European biotechnology company with development, validation and related laboratory services to support implementation of a proprietary precision oncology predictive device for use in the United States. Successful completion of the program could lead to ongoing commercial testing and CLIA-related service revenues.

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.